In a filing, Arrowhead Pharmaceuticals Inc revealed its Chief Executive Officer Anzalone Christopher Richard unloaded Company’s shares for reported $0.77 million on Mar 13 ’25. In the deal valued at $15.07 per share,51,425 shares were sold. As a result of this transaction, Anzalone Christopher Richard now holds 4,062,377 shares worth roughly $63.37 million.
Then, Anzalone Christopher Richard bought 51,425 shares, generating $774,785 in total proceeds.
Before that, Anzalone Christopher Richard sold 166,667 shares. Arrowhead Pharmaceuticals Inc shares valued at $3,005,006 were divested by the Chief Executive Officer at a price of $18.03 per share. As a result of the transaction, Anzalone Christopher Richard now holds 3,907,135 shares, worth roughly $60.95 million.
Goldman initiated its Arrowhead Pharmaceuticals Inc [ARWR] rating to a Neutral in a research note published on June 05, 2024; the price target was $31. A number of analysts have revised their coverage, including BofA Securities’s analysts, who began to cover the stock in early December with a ‘”a Buy”‘ rating. Citigroup began covering ARWR with “Neutral” recommendation on September 19, 2023. TD Cowen started covering the stock on July 21, 2023. It rated ARWR as “an Outperform”.
Price Performance Review of ARWR
On Monday, Arrowhead Pharmaceuticals Inc [NASDAQ:ARWR] saw its stock jump 1.56% to $15.60. Over the last five days, the stock has gained 2.56%. Arrowhead Pharmaceuticals Inc shares have fallen nearly -17.02% since the year began. Nevertheless, the stocks have fallen -45.44% over the past one year. While a 52-week high of $30.41 was reached on 02/07/25, a 52-week low of $14.23 was recorded on 03/11/25. SMA at 50 days reached $18.92, while 200 days put it at $21.88.
Levels Of Support And Resistance For ARWR Stock
The 24-hour chart illustrates a support level at 15.12, which if violated will result in even more drops to 14.63. On the upside, there is a resistance level at 15.97. A further resistance level may holdings at 16.34. The Relative Strength Index (RSI) on the 14-day chart is 35.84, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -1.51, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 76.11%. Stochastics %K at 19.43% indicates the stock is a buying.
How much short interest is there in Arrowhead Pharmaceuticals Inc?
A steep rise in short interest was recorded in Arrowhead Pharmaceuticals Inc stocks on 2025-02-28, dropping by -0.87 million shares to a total of 9.2 million shares. Yahoo Finance data shows the prior-month short interest on 2025-01-31 was 10.06 million shares. There was a decline of -9.41%, which implies that there is a negative sentiment for the stock.
